+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Colistimethate Sodium for Injection Market - Global Forecast 2026-2032- Product Image
Colistimethate Sodium for Injection Market - Global Forecast 2026-2032- Product Image
New

Colistimethate Sodium for Injection Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6124265
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Colistimethate Sodium for Injection Market grew from USD 50.54 million in 2025 to USD 58.89 million in 2026. It is expected to continue growing at a CAGR of 11.81%, reaching USD 110.43 million by 2032.

A comprehensive introduction that outlines the clinical role, formulation choices, and delivery considerations shaping colistimethate sodium injection utilization in modern care settings

Colistimethate sodium for injection occupies a critically important position in the therapeutic arsenal against multidrug-resistant Gram-negative infections. Clinically, it is deployed in severe bloodstream infections, complicated lower respiratory tract infections, challenging skin and soft tissue infections, and select urinary tract infections where alternative agents are ineffective or contraindicated. As resistance to contemporary beta-lactams and carbapenems has risen, clinicians have returned to older polymyxin-class agents like colistimethate sodium, balancing potent antibacterial activity against known safety considerations such as nephrotoxicity and neurotoxicity.

From a formulation and delivery perspective, the injectable product exists in multiple dosage forms and routes, which shape hospital administration practices and procurement preferences. Intravenous administration is predominant for systemic infections, whereas inhalation is increasingly used as an adjunctive approach in ventilator-associated complications. Additionally, distinctions between lyophilized powder that requires reconstitution and ready-to-use solutions influence pharmacy workflow and bedside efficiency. Taken together, these clinical, formulation, and delivery characteristics define the decision criteria for clinicians, pharmacy leaders, and purchasing groups evaluating the role of colistimethate sodium within treatment protocols.

How clinical resistance dynamics, stewardship protocols, and sterile manufacturing advances are reshaping therapeutic practice and procurement strategies for colistimethate sodium injection

The therapeutic and commercial landscape for colistimethate sodium injection is undergoing transformative shifts driven by antimicrobial resistance trends, evolving hospital practice standards, and innovations in sterile injectable manufacturing. Clinically, the expanding prevalence of carbapenem-resistant Enterobacterales and multidrug-resistant Acinetobacter species has elevated reliance on polymyxin-class therapies as salvage or combination regimens, prompting more frequent stewardship-led protocols that standardize dosing and monitoring to mitigate toxicity risks.

Operationally, hospitals and integrated delivery networks are accelerating adoption of ready-to-use infusion preparations and automated compounding technologies to reduce preparation time, limit contamination risk, and improve dosing accuracy. Concurrently, supply chain modernization - including strategic dual-sourcing, regional sterile fill-finish partnerships, and increased transparency around API origins - is reshaping procurement strategies. Regulatory scrutiny and post-marketing safety surveillance are also intensifying, with stakeholders demanding robust real-world evidence and pharmacovigilance data to support formulary decisions and optimize therapeutic pathways.

Analysis of how 2025 United States tariff changes have compounded supply chain, sourcing, and procurement dynamics affecting colistimethate sodium injection availability and commercial strategies

Cumulative adjustments to United States tariff schedules and related trade policy changes enacted through 2025 have created a layered impact on the injectable pharmaceuticals ecosystem that includes colistimethate sodium. Increased duties on select active pharmaceutical ingredients and intermediates, combined with higher freight and compliance-associated costs, have elevated landed costs for some producers that rely on globally distributed supply chains. As a result, manufacturers and distributors have reassessed sourcing strategies, shifting weight toward suppliers with nearshore capabilities or vertically integrated supply chains to reduce exposure to tariff volatility and shipping disruptions.

These adaptations have had ripple effects across procurement behavior in health systems. Pharmacy purchasing teams are placing added emphasis on contractual flexibility, contingency stock levels, and clearer escalation protocols with suppliers. Meanwhile, manufacturers with diversified manufacturing footprints and compliant, inspected fill-finish sites have been better positioned to absorb incremental duty costs or negotiate pass-through pricing with institutional buyers. Overall, the tariff-driven pressures of 2025 accelerated pre-existing trends toward supply chain resilience, encouraging stakeholders to prioritize continuity, regulatory compliance, and traceability amid evolving trade landscapes.

Strategic segmentation insights revealing how indications, routes, dosage forms, end-user settings, and patient cohorts uniquely influence clinical deployment and procurement of colistimethate sodium injection

Segmentation provides a structured lens to understand clinical use patterns, procurement drivers, and formulation preferences for colistimethate sodium injection. By indication, clinical demand is concentrated in bloodstream infections, which encompasses primary and secondary bacteremia presentations, and serious lower respiratory tract infections that include community-acquired, hospital-acquired, and ventilator-associated pneumonias. Skin and soft tissue infections represent another significant pool of clinical need, covering cellulitis, surgical site infections, and wound infections, while urinary tract infections are differentiated between complicated and uncomplicated presentations that influence dosing and duration decisions.

Route of administration segmentation highlights divergent operational implications: inhalation routes support adjunctive respiratory strategies, intramuscular options have niche applications, and intravenous use - whether by continuous infusion or intermittent infusion - remains the principal modality for systemic therapy. Dosage form distinctions between lyophilized powder and ready-to-use solutions affect pharmacy compounding demands and bedside readiness; within those families, multi-dose versus single-dose vials and infusion bag versus prefilled syringe configurations have distinct implications for waste, sterility practices, and inventory control. Finally, end-user segmentation spanning ambulatory care centers, outpatient and specialty clinics, general wards, and intensive care units, together with patient population stratifications across adult, geriatric, adolescent, child, infant, and neonatal cohorts, informs targeted clinical pathways and formulary placement decisions.

Regional dynamics and infrastructure considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory practices, supply chains, and clinical adoption of colistimethate sodium injection

Regional dynamics exert meaningful influence on regulatory pathways, supply chain architecture, and clinical adoption patterns for colistimethate sodium injection. In the Americas, hospital networks and academic medical centers play a leading role in defining clinical protocols and stewardship approaches, and North American supply chains emphasize regulatory compliance and inspected sterile fill-finish capacity. This region often drives rigorous post-authorization safety monitoring and formulary evaluations that influence global clinical practice.

Europe, Middle East & Africa presents a heterogeneous landscape where centralized procurement mechanisms coexist with fragmented national regulatory frameworks. In these markets, price sensitivity, national antimicrobial guidelines, and variable access to advanced compounding infrastructure shape how colistimethate sodium is procured and administered. Policymakers and regional health authorities in several jurisdictions are simultaneously prioritizing antimicrobial resistance containment programs and investments in hospital pharmacy capabilities. Asia-Pacific is characterized by rapid capacity expansion in sterile manufacturing, a growing emphasis on hospital-level adoption in tertiary care facilities, and diverse payer models. The region also demonstrates significant variation in clinical practice patterns, with several centers of excellence advancing combination therapy approaches and clinical research initiatives that inform global understanding of polymyxin use.

How manufacturers, contract providers, and clinical partners are aligning manufacturing resilience, formulation advancements, and evidence programs to strengthen supply and clinical adoption of injectable colistimethate sodium

Companies engaged with colistimethate sodium injectables are evolving along complementary strategic pathways centered on manufacturing reliability, formulation innovation, and partnerships with clinical stakeholders. Some organizations prioritize investments in sterile fill-finish capacity and quality systems to reduce lot-level variability and support rapid response to demand surges. Others focus on enhancing convenience and safety through development of ready-to-use solutions, prefilled syringes, or improved vial presentations that reduce preparation time and lower contamination risk.

Across the competitive landscape, contract development and manufacturing organizations have emerged as critical enablers, offering scalable sterile production and regulatory support for firms seeking to diversify supply. Commercial strategies increasingly combine evidence-generation programs, including real-world outcomes and pharmacokinetic/pharmacodynamic studies, with hospital education initiatives and stewardship collaborations to demonstrate safe, effective utilization. Firms that align manufacturing resilience with clinician-focused product features and robust safety communication are best positioned to sustain long-term institutional partnerships and uptake.

Practical strategic actions for manufacturers, distributors, and health systems to secure supply continuity, optimize clinical use, and accelerate adoption of higher-convenience formulations

Industry leaders should prioritize a set of actionable measures to safeguard supply continuity and enhance clinical utility of colistimethate sodium injection. First, diversify sourcing across multiple geographies and qualified suppliers, while advancing nearshore or regional fill-finish arrangements to reduce exposure to trade policy shocks and shipping constraints. Second, accelerate adoption of ready-to-use formulations and prefilled systems where clinically appropriate to streamline pharmacy workflow and improve patient safety, while ensuring compatibility with stewardship dosing protocols.

Third, invest in targeted evidence generation that addresses safety, dosing optimization, and real-world outcomes across defined patient cohorts, thereby supporting formulary acceptance and clinician confidence. Fourth, strengthen relationships with hospital pharmacy and infectious disease stakeholders through joint stewardship initiatives and operational pilots that quantify preparation time, waste reduction, and monitoring burden. Finally, incorporate flexible contracting terms and contingency inventory clauses into supplier agreements to provide procurement teams with practical tools for responding to episodic supply disruptions and evolving clinical demand patterns.

A transparent mixed-methods research approach integrating clinician and supply chain expert interviews with regulatory and clinical evidence synthesis to ensure robust and actionable insights

The research methodology combined structured primary engagements with subject-matter experts and a comprehensive secondary review of regulatory filings, clinical guidelines, pharmacovigilance databases, and peer-reviewed literature to create a robust evidence foundation. Primary inputs included interviews with infectious disease clinicians, hospital pharmacy directors, supply chain leads, and manufacturing quality experts to capture frontline experiences with dosing paradigms, preparation workflows, and supplier performance. These conversations were complemented by site visits and virtual facility assessments to validate manufacturing capabilities and quality systems.

Secondary analysis synthesized regulatory documents, label changes, clinical guidance statements, and published observational studies to contextualize real-world utilization and safety considerations. Data triangulation techniques ensured consistency across diverse inputs, and sensitivity checks were applied to reconcile differing stakeholder perspectives. Throughout the process, emphasis was placed on transparency of assumptions, traceability of source material, and documenting areas where evidence gaps remain, thereby enabling readers to understand the confidence and limitations associated with each analytical conclusion.

A concise conclusion highlighting the interplay of resistance, stewardship, and supply resilience that will determine the clinical availability and safe use of injectable colistimethate sodium

In summary, colistimethate sodium injection remains a vital therapeutic option in settings that confront multidrug-resistant Gram-negative infections, with clinical value shaped by indication-specific needs, route of administration choices, and dosage form preferences. The confluence of antimicrobial resistance pressures, evolving stewardship practices, and supply chain realignments underscores the need for proactive strategies that balance clinical efficacy with safety and operational efficiency. Stakeholders who invest in diversified sourcing, readiness for ready-to-use formulations, and collaborative evidence generation will be better equipped to navigate emerging challenges.

Looking ahead, the interplay between regional manufacturing capacity, regulatory requirements, and hospital-level stewardship programs will determine how readily available and safely administered colistimethate sodium remains as a treatment option. By aligning procurement strategies, clinical education, and formulation innovation, stakeholders can sustain access while optimizing patient outcomes and minimizing administration risk. The findings presented here are intended to guide operational decisions and clinical policy discussions grounded in contemporary practice and supply realities.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Colistimethate Sodium for Injection Market, by Indication
8.1. Bloodstream Infection
8.1.1. Primary Bacteremia
8.1.2. Secondary Bacteremia
8.2. Lower Respiratory Tract Infection
8.2.1. Community Acquired Pneumonia
8.2.2. Hospital Acquired Pneumonia
8.2.3. Ventilator Associated Pneumonia
8.3. Skin And Soft Tissue Infection
8.3.1. Cellulitis
8.3.2. Surgical Site Infection
8.3.3. Wound Infection
8.4. Urinary Tract Infection
8.4.1. Complicated Urinary Tract Infection
8.4.2. Uncomplicated Urinary Tract Infection
9. Colistimethate Sodium for Injection Market, by Dosage Form
9.1. Lyophilized Powder
9.1.1. Multi Dose Vial
9.1.2. Single Dose Vial
9.2. Ready To Use Solution
9.2.1. Infusion Bag
9.2.2. Prefilled Syringe
10. Colistimethate Sodium for Injection Market, by Patient Population
10.1. Adult
10.2. Geriatric
10.3. Pediatric
10.3.1. Adolescent
10.3.2. Child
10.3.3. Infant
10.3.4. Neonatal
11. Colistimethate Sodium for Injection Market, by Route Of Administration
11.1. Inhalation
11.2. Intramuscular
11.3. Intravenous
11.3.1. Continuous Infusion
11.3.2. Intermittent Infusion
12. Colistimethate Sodium for Injection Market, by End User
12.1. Ambulatory Care Center
12.2. Clinic
12.2.1. Outpatient Clinic
12.2.2. Specialty Clinic
12.3. Hospital
12.3.1. General Ward
12.3.2. Intensive Care Unit
13. Colistimethate Sodium for Injection Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Colistimethate Sodium for Injection Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Colistimethate Sodium for Injection Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Colistimethate Sodium for Injection Market
17. China Colistimethate Sodium for Injection Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott
18.6. Fresenius Kabi AG
18.7. Gland Pharma Limited
18.8. Hikma Pharmaceuticals PLC
18.9. Lupin Limited
18.10. Pfizer Inc.
18.11. Sagent Pharmaceuticals, Inc.
18.12. Sandoz International GmbH
18.13. Teva Pharmaceutical Industries Ltd.
18.14. Viatris Inc.
18.15. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PRIMARY BACTEREMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PRIMARY BACTEREMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PRIMARY BACTEREMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SECONDARY BACTEREMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SECONDARY BACTEREMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SECONDARY BACTEREMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY VENTILATOR ASSOCIATED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY VENTILATOR ASSOCIATED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY VENTILATOR ASSOCIATED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CELLULITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CELLULITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CELLULITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SURGICAL SITE INFECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SURGICAL SITE INFECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SURGICAL SITE INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY WOUND INFECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY WOUND INFECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY WOUND INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY UNCOMPLICATED URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY UNCOMPLICATED URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY UNCOMPLICATED URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFUSION BAG, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFUSION BAG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFUSION BAG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CHILD, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CHILD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY NEONATAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CONTINUOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CONTINUOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTERMITTENT INFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTERMITTENT INFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTERMITTENT INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GENERAL WARD, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GENERAL WARD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GENERAL WARD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
TABLE 138. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 139. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 142. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
TABLE 143. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
TABLE 144. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
TABLE 145. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 146. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 147. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 148. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
TABLE 150. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 199. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 200. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 201. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
TABLE 202. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 203. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
TABLE 204. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 205. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 206. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
TABLE 207. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
TABLE 208. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
TABLE 209. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 210. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 211. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 212. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
TABLE 214. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 216. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 217. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
TABLE 218. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 219. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
TABLE 220. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 221. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 222. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
TABLE 223. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
TABLE 224. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
TABLE 225. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 226. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 227. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 228. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 229. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
TABLE 230. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 231. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 233. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
TABLE 234. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 235. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
TABLE 236. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 237. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 238. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
TABLE 239. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
TABLE 240. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
TABLE 241. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 242. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 243. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 244. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 245. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
TABLE 246. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 247. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 248. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 249. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
TABLE 250. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 251. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
TABLE 252. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 253. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 254. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
TABLE 255. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
TABLE 256. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
TABLE 257. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
TABLE 258. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 259. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
TABLE 260. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 261. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
TABLE 262. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 263. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 264. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 265. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 266. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
TABLE 267. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 268. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
TABLE 269. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
TABLE 270. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 271. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
TABLE 272. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
TABLE 273. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
TABLE 274. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY

Companies Mentioned

The key companies profiled in this Colistimethate Sodium for Injection market report include:
  • Abbott
  • Fresenius Kabi AG
  • Gland Pharma Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Pfizer Inc.
  • Sagent Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Injection Cefuroxime Sodium Market - Global Forecast 2025-2030 - Product Image

Injection Cefuroxime Sodium Market - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Ertapenem Sodium for Injection Market - Global Forecast 2025-2030 - Product Image

Ertapenem Sodium for Injection Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Sodium Hyaluronate Injection for Osteoarthritis Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Sodium Hyaluronate Injection for Osteoarthritis Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 112 Pages
  • Global
From
Lactated Ringer's Injection Market - Global Strategic Business Report - Product Image

Lactated Ringer's Injection Market - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Facet-Joint Injection Global Market Report 2025 - Product Image

Facet-Joint Injection Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.